These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 25239825)

  • 21. [Proinsulin C-peptide -- the bioactive peptide with a huge promise].
    Walenciak Ł; Fendler W; Młynarski W
    Pediatr Endocrinol Diabetes Metab; 2007; 13(2):95-8. PubMed ID: 17880815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New frontiers in the management of type 2 diabetes.
    Mudaliar S
    Indian J Med Res; 2007 Mar; 125(3):275-96. PubMed ID: 17496356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Glycemic control and diabetic complications].
    Yamada Y
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():604-8. PubMed ID: 15999778
    [No Abstract]   [Full Text] [Related]  

  • 24. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy.
    Thompson DM; Meloche M; Ao Z; Paty B; Keown P; Shapiro RJ; Ho S; Worsley D; Fung M; Meneilly G; Begg I; Al Mehthel M; Kondi J; Harris C; Fensom B; Kozak SE; Tong SO; Trinh M; Warnock GL
    Transplantation; 2011 Feb; 91(3):373-8. PubMed ID: 21258272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical utility of insulin and insulin analogs.
    Sanlioglu AD; Altunbas HA; Balci MK; Griffith TS; Sanlioglu S
    Islets; 2013; 5(2):67-78. PubMed ID: 23584214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prevalence of diabetes, antidiabetic treatment and chronic diabetic complications reported by general practitioners].
    Fabian W; Majkowska L; Stefański A; Moleda P
    Przegl Lek; 2005; 62(4):201-5. PubMed ID: 16229234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hypoglycemic treatment of type 2 diabetes].
    Thorsby P; Kilhovd B; Sletmo R; Martinsen S; Birkeland KI
    Tidsskr Nor Laegeforen; 2000 Aug; 120(20):2434-40. PubMed ID: 11475233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes.
    Lebovitz HE
    Diabetes Care; 1999 Apr; 22 Suppl 3():C41-4. PubMed ID: 10189561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical value of C-peptide determination].
    Meier C; Ladewig A; Keller U; Berger W
    Praxis (Bern 1994); 1997 Aug; 86(34):1289-95. PubMed ID: 9381016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of insulin delivery devices in diabetes care.
    Garg SK
    Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S1-3. PubMed ID: 20515296
    [No Abstract]   [Full Text] [Related]  

  • 31. The clinical characteristics of latent autoimmune diabetes in adults and its relation with chronic complications in metabolically poor controlled Turkish patients with Type 2 diabetes mellitus.
    Arikan E; Sabuncu T; Ozer EM; Hatemi H
    J Diabetes Complications; 2005; 19(5):254-8. PubMed ID: 16112499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus.
    Paisley AN; Savage MW; Wiles PG
    Diabet Med; 2009 Sep; 26(9):935-8. PubMed ID: 19719716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of insulin therapy on macrovascular risk factors in type 2 diabetes.
    Boyne MS; Saudek CD
    Diabetes Care; 1999 Apr; 22 Suppl 3():C45-53. PubMed ID: 10189562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lung microangiopathy in diabetes].
    Kuziemski K; Górska L; Jassem E; Madej-Dmochowska A
    Pneumonol Alergol Pol; 2009; 77(4):394-9. PubMed ID: 19722145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Vascular wall and diabetes mellitus: what complications and why?].
    Marre M
    Therapie; 1997; 52(5):371-4. PubMed ID: 9501559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Differential diagnosis of insulin- and noninsulin-dependent diabetes mellitus--are there therapeutic implications?].
    Tappy L; Fröhlich FE
    Praxis (Bern 1994); 1994 Dec; 83(50):1406-9. PubMed ID: 7801016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [C-peptide and its role as a predicator of the cardiovascular complications].
    Shklovskiĭ BL; Baksheev VI; Oĭnotkinova OSh; Serebrennikov VN
    Voen Med Zh; 2013 Nov; 334(11):48-54. PubMed ID: 24611309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C-peptide, Na+,K(+)-ATPase, and diabetes.
    Vague P; Coste TC; Jannot MF; Raccah D; Tsimaratos M
    Exp Diabesity Res; 2004; 5(1):37-50. PubMed ID: 15198370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes.
    Kamiya H; Zhang W; Sima AA
    Ann Neurol; 2004 Dec; 56(6):827-35. PubMed ID: 15497155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preventing macrovascular disease in patients with type 2 diabetes mellitus.
    Johansen OE; Birkeland KI
    Am J Cardiovasc Drugs; 2003; 3(4):283-97. PubMed ID: 14728081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.